Amylyx Pharmaceuticals, Inc. — Q2 2022 Form 10-Q
Business context and reporting period. The unaudited quarter and six months ended June 30, 2022 cover Amylyx’s transition toward commercialization of AMX0035 for ALS, alongside continued clinical development. The company had no product sales through June 30. Health Canada granted conditional marketing authorization for ALBRIOZA in June; the Canadian launch occurred July 29, 2022, after quarter-end.
Financial performance and position
Amounts below are in millions of dollars except per-share data. Amylyx reported no product revenue; gross margins are therefore not meaningful. Results primarily reflect research, development and commercialization-readiness costs.
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Research and development expense | $24.3 | $10.9 | $45.7 | $17.8 |
| General and administrative expense | $30.0 | $7.7 | $56.3 | $13.7 |
| Total operating expenses | $54.3 | $18.6 | $102.1 | $31.5 |
| Net loss | $54.1 | $21.9 | $101.9 | $36.4 |
| Basic and diluted net loss per share | $(0.93) | $(3.41) | $(1.85) | $(5.75) |
| Cash used in operating activities | Not separately provided for the quarter | $87.1 | $25.7 |
- At June 30, cash and cash equivalents were $67.4 million and short-term investments were $139.2 million, totaling $206.7 million. Total assets were $225.2 million; current liabilities were $27.2 million and total liabilities were $32.5 million.
- The company reported no outstanding convertible notes or other debt at June 30. Operating lease liabilities totaled $7.1 million.
- Accumulated deficit was $257.8 million. The January 2022 IPO generated approximately $196.4 million in net proceeds; the filing states that $90.6 million of those proceeds had been used by June 30.
Material changes versus comparable periods
- Q2 operating expenses increased 192% and net loss increased 147% year over year. For the six-month period, operating expenses rose 224% and net loss rose 180%.
- Management attributed higher R&D costs mainly to the PHOENIX Phase 3 ALS trial, manufacturing development and pre-commercialization work. Higher G&A reflected expanded commercial and administrative staffing, stock-based compensation, consulting, professional services and public-company costs.
- Six-month operating cash use rose to $87.1 million from $25.7 million. Financing cash flow of $199.6 million, mainly from the IPO, was partly deployed into short-term investments; investing activities used $94.8 million.
- Per-share losses improved despite the higher net loss, principally in the context of the substantial increase in weighted-average shares following the IPO and preferred-stock conversion.
Outlook, commentary and risks
- Management expected cash, cash equivalents and short-term investments at June 30 to fund operating and capital needs for at least 12 months after the filing date. It cautioned that this estimate depends on assumptions and that additional financing may be needed.
- The FDA review of the U.S. NDA was extended, with a PDUFA target date of September 29, 2022; the FDA scheduled a further advisory committee meeting for September 7. The March 2022 committee vote on whether existing trial data established efficacy was 4 in favor and 6 opposed. The FDA’s decision is non-binding on the committee’s recommendation, and the filing says additional clinical data may be required.
- The PHOENIX Phase 3 trial was ongoing, with U.S. enrollment complete and European enrollment continuing. Management anticipated topline results in 2024. The European application remained under review, with a decision expected in the first half of 2023.
- Canadian authorization is conditional and includes providing PHOENIX and other study data. The filing identifies regulatory uncertainty, commercialization and reimbursement challenges, dependence on third-party manufacturers and suppliers, trial execution, competition, and potential COVID-19-related disruptions as material risks.
- The company has contingent grant-related royalty obligations. Certain ALS grants may require payments totaling 150% of grant funding through specified mechanisms; Alzheimer’s-related grant agreements provide for payments up to $45 million in aggregate. No liability was recorded because triggering conditions had not occurred.
- Management reported disclosure controls and procedures were effective at a reasonable-assurance level as of June 30. It also described previously identified material weaknesses in financial reporting controls as remediated, while noting future control risks.
Important facts for investors to verify
- FDA review outcome and any resulting data requirements, alongside the timing and results of PHOENIX.
- Canadian ALBRIOZA launch progress, uptake, pricing and reimbursement, and fulfillment of authorization conditions.
- Actual cash burn and runway relative to management’s at-least-12-month estimate, including future financing needs and dilution risk.
- European regulatory timing and whether manufacturing capacity and supply can support clinical and commercial needs.
- Potential grant royalty obligations and the effect of stock-based compensation and share-based awards on future dilution.